Who’s Developing What in Drug Delivery 2005?

Research and Markets (http://www.researchandmarkets.com/reports/c26300) has announced the addition of Who’s Developing What in Drug Delivery 2005? to their offering.

A new 850 page management report that analyses the structure, performance, R&D and products of over 125 leading drug delivery companies.

Industry and commercial interest in drug delivery continues to build steadily. The benefits to patients can be seen in improved compliance and medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes and bring new therapies to the market that would, previously, have been impossible.

The drug delivery sector has evolved from being simply a part of the pharmaceutical production process to a driving force for innovation and profits. As a result, developers of drug delivery products and technology have seen significant attention from customers and investors alike, and merger and acquisition activity is notable.

Who’s Developing What in Drug Delivery? is a new management report that provides comprehensive analysis of more than 125 leading players in the drug delivery field. Subjects covered in the report include:

 –         Company Overview –         Key Personnel –         Key Milestones –         Competition and Competing Products –         Products/Technologies –         R&D and Research Strategy –         Agreements –         Financial Data –         Comprehensive Contact Details  Leading drug delivery companies included:  – 3M DDS – aaiPharma – Access Pharmaceuticals – Acusphere – Acrux – Advanced Drug Delivery – Technologies – Aerogen – Alizyme – Alkermes – AlphaRx – AlphaVax – Altea Therapeutics – ALZA Corporation – Andrx Corporation – Antares Pharma – AP Pharma – Aradigm Corporation – Baxa Corporation – Baxter – Bentley Pharmaceuticals – Bespak – BioDelivery Sciences – Bioject Medical Technologies – BioProgress – BioSante Pharmaceuticals – Biovail Corporation – Bradley Pharmaceuticals – Camurus – Cardinal Health, Alaris – Cellegy Corporation – Cennapharm – Chiron Corporation – CIMA Labs – Columbia Laboratories – Control Delivery Systems – Curlin Medical – CyDex – DebioPharm – Delcath Systems – Delsite Biotechnologies – DepoMed – Diatos – Direct-Haler – DOR Biopharma – Durect Corporation – DUSA Pharmaceutical – Eiffel Technologies – Elan Corporation – Elite Pharmaceuticals – Emisphere Technologies – Encap Drug Delivery – Endovasc – Enpath Medical – Enzon – Ethypharm – Eurand – Evit Labs – Expression Genetics – Fertin Pharma – Flamel Technologies – FzioMed – Generex Biotechnology – Corporation – Glycologic – Hospira – Idea – Impax Laboratories – INEX Pharmaceuticals – Innovata Biomed – InSite Vision – Intransal Technologies – Iomai Corporation – Iomed – Kos Pharmaceuticals – KV Pharmaceuticals – Labopharm – LAM Pharmaceutical – Corporation – LaviPharm Corporation – LecTec Corporation – Light Sciences Corporation – Lipid Technologies Provider – Lyfjathroun – Biopharmaceuticals – MacroChem Corporation – MacroMed – MaxCyte – McKinley Medical – MedImmune – MicroCHIPS – Milestone Scientific – Miravant Medical – Technologies – Nanotherapeutics – Nastech Pharmaceutical – Nektar Therapeutics – NeoPharm – Neurotech – NexMed – Njex – Nobex Corporation – Norwood Abbey – NovaDel Pharma – Novagli Pharma – Novavax – Noven Pharmaceuticals – Oakwood Laboratories – OctoPlus – Oriel Therapeutics – Penwest Pharmaceuticals – Phoqus Pharmaceuticals – PhotoCure – Point Biomedical – Corporation – QLT – Respironics – Scolr – Shire Laboratories – Skinvisible – SkyePharma – Sontra Medical – Corporation – Sonus Pharmaceuticals – Spherics – Supratek Pharma – Synt:em – Syntonix Pharmaceuticals – The Medical House – TransPharma Medical – Unigene Laboratories – Valentis – Valera Pharmaceuticals – Vectura – Ventaira – Vivier Pharma – Vivus 

For more information visit http://www.researchandmarkets.com/reports/c26300